Common Sense for Drug Policy Blog

NOVEMBER 29, 2023

Receipt of Opioid Use Disorder Treatments Prior to Fatal Overdoses and Comparison to No Treatment "The findings revealed that exposures to MOUD, even if not continued throughout the six-month exposure period was associated with reduced risk of a fatal poisoning compared to non-MOUD forms of treatment and no treatment exposure.

Treatment 52

Treatment Drugs 52

SCIENMAG: Medicine & Health

JUNE 8, 2023

Statement Highlights: A new American Heart Association scientific statement focuses on treatment strategies for pediatric cardiomyopathy (diseases of the heart muscle’s structure and function that may lead to heart failure and death) and is a companion to a 2019 scientific statement focused on diagnosis of the condition.

Treatment 61

Treatment Disease 61

The Pharma Data

DECEMBER 22, 2020

22, 2020 — Before the COVID-19 pandemic hit, life expectancy in the United States rose in 2019 for the second year in a row, according to two new federal government reports. That would be a new record and represent 400,000 more deaths than were recorded for 2019. TUESDAY, Dec. history, according to the Associated Press.

Disease 52

Disease Government Treatment Drugs 52

Creative Biolabs

JANUARY 15, 2020

The production of new drugs and biological products means providing patients with new treatment options, which has greatly promoted progress in the field of health care.

Clinical Trials 52

Clinical Trials FDA Trials Drugs 52

Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). How does the DCI mechanism compare to the design of other drugs for cancer treatment?

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

BioPharma Drive: Drug Pricing

AUGUST 28, 2023

The treatment, developed by a biotech Bayer acquired in 2019, appeared safe in a small trial and showed signs of an effect on disease progression.

Therapies 98

Therapies Trials Treatment Disease 98

ASPET

JUNE 6, 2024

In keeping with NCCIH's natural product research priorities and in recognizing this gap in knowledge, NCCIH formally launched a research program in 2019 to expand research on the potential therapeutic benefit of minor cannabinoids and terpenes for the treatment of pain.

Research 100

Research Production Treatment 100

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. ERLEADA ® is an androgen receptor (AR) inhibitor indicated for the treatment of patients with nmCRPC and for the treatment of patients with mCSPC. 10 months. [5]

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

The Pharma Data

SEPTEMBER 9, 2020

CERENOVUS Launches New Suite of Technologies to Advance Stroke Treatment. CERENOVUS Launches New Suite of Technologies to Advance Stroke Treatment. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke. Stroke Research and Treatment, Hindawi, 27 Nov.

Treatment 52

Treatment Production Science Disease 52

The Pharma Data

JANUARY 17, 2021

This coverage provides a minimally invasive treatment alternative for eligible patients. “Not being able to breathe really limits the ability of patients to go about their daily lives, and for those who qualify for the treatment, endobronchial valves can make a big difference.” 1354-1362, 2019.

Treatment 52

Treatment Clinical Trials Trials Disease 52

Broad Institute

JULY 10, 2024

A three-drug cocktail known as Trikafta has greatly improved patient quality of life since its development in 2019, but can cause cataracts and liver damage and must be taken daily at a cost of about $300,000 per year. With further development, it could pave the way for treatments that are administered only once and have fewer side effects.

Engineering 145

Engineering Packaging DNA Treatment 145

The Pharma Data

FEBRUARY 22, 2021

Efanesoctocog alfa, a novel and investigational factor VIII therapy independent of von Willebrand Factor, is designed to provide near-normal factor activity levels for the majority of the week in a once-weekly prophylactic treatment regimen. In 2019, Sobi’s revenues amounted to SEK 14.2

FDA 52

FDA Treatment Therapies International 52

Drug Discovery Today

DECEMBER 17, 2019

December 10, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has completed clinical production of Bridge Therapeutics Inc.’s Somerset, N.J. Birmingham, Ala.–

Production 100

Production Licensing Licensing Treatment 100

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

Agency IQ

OCTOBER 6, 2023

In a first, FDA tackles treatments for stimulant use disorder A new draft guidance from the FDA gives developers a roadmap to advance the development of novel therapies to address stimulant use disorders. SAMSHA published an “ evidence-based resource guide ” on substance use disorder treatment in June 2020.

FDA 40

FDA Treatment Production Trials 40

The Pharma Data

MAY 16, 2022

Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). There is no cure for HIV or AIDS. About Lenacapavir.

FDA 52

FDA Treatment Science Therapies 52

Common Sense for Drug Policy Blog

MAY 8, 2024

People Incarcerated in US Jails Receiving Medication for Opioid Use Disorder "At midyear 2019, the highest percentage of confined persons receiving MAT was reported in jails in the Northeast (3%), followed by jails in the Midwest and West (1% each) and jails in the South (0.4%) (table 7). or more per 100,000 U.S. Maruschak, Todd D.

Treatment 52

Treatment 52

Chemical Biology and Drug Design

OCTOBER 5, 2023

Aromatic aldehydes, which increase the oxygen affinity of human hemoglobin to prevent polymerization of sickle hemoglobin and inhibit red blood cell (RBC) sickling, have been the subject of keen interest for the development of effective treatment against SCD.

Metabolic Stability 100

Metabolic Stability Treatment Disease Research 100

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has approved EYSUVIS for the short-term treatment of dry eye disease. . EYSUVIS is the first FDA-approved corticosteroid specifically for dry eye disease treatment. Over-the-counter treatments fail due to the body’s natural protective system. 25% for dry eye disease treatment.

Disease 52

Disease Treatment FDA FDA Approval 52

Common Sense for Drug Policy Blog

DECEMBER 20, 2023

This number decreased to 305 by 2019 and again to 296 by the end of 2021. These data indicate a 3% decrease in JDCs between 2019 and 2021. Data Digest Issue 2: Treatment Court Counts. Overall, between 2014 and 2021, the number of JDCs in the United States decreased by 30%."

Drugs 52

Drugs Treatment 52

Common Sense for Drug Policy Blog

AUGUST 26, 2024

million deaths were attributable to alcohol consumption in 2019, representing 4.7% dwf_admin Mon, 08/26/2024 - 12:56 Source Global status report on alcohol and health and treatment of substance use disorders. . "• Worldwide, 2.6 of all DALYs among males and 0.6 million deaths and 2.0% Geneva: World Health Organization; 2024.

Disease 52

Disease Treatment 52

National Institute on Drug Abuse: Nora's Blog

JULY 22, 2024

People with an opioid use disorder (OUD) urgently need treatment not just to protect them from overdosing but also to help them achieve recovery, but highly effective medications like buprenorphine and methadone remain underused. Almost all (99%) of those retained in treatment achieved remission.

Pharmacy 83

Pharmacy Treatment Community Pharmacies Trials 83

Common Sense for Drug Policy Blog

NOVEMBER 8, 2024

Forced or coerced sexual acts or other sexual activity with facility staff included sexual activity involving physical force, threat of force, or other forms of pressure or coercion, such as being given money, favors, protection, or special treatment or being repeatedly asked to engage in sexual activity. December 2019. NCJ253042.

Treatment 52

Treatment 52

The Pharma Data

JANUARY 14, 2021

Department of Health and Human Services’ (HHS) decision to effectively remove the “X-waiver” requirement for physicians, expanding their ability to utilize medication-assisted treatment (MAT) for patients struggling with opioid use disorder (OUD). Added Dr. Rosenberg, “This is a great day for our patients.

Treatment 52

Treatment Licensing Licensing Hospitals 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Common Sense for Drug Policy Blog

MAY 8, 2024

Opioid Use Disorder Screenings in Local Jails "Between June 1 and June 30, 2019, an estimated 894,030 persons were admitted to local jails (table 3). Larger jail jurisdictions (those holding 1,000 or more inmates) reported that 79% of persons admitted in June 2019 were screened for OUD. or more per 100,000 U.S. Maruschak, Todd D.

Treatment 52

Treatment 52

BioPharma Drive: Drug Pricing

AUGUST 18, 2023

The treatment, which Merck picked up through a 2019 acquisition of Peloton Therapeutics, helped delay disease progression in patients with advanced renal cell carcinoma.

Treatment 52

Treatment Disease Drugs 52

The Pharma Data

NOVEMBER 18, 2021

Eli Lilly and Company blazoned that registration is now open for the CHALLENGE-MIG clinical trial, the first and only head-to- head trial comparing twoanti-calcitonin gene- related peptide (CGRP) drugs for the preventative treatment of episodic migraine in grown-ups.1 gepants) may help people achieve the pretensions that count most to them.

Treatment 52

Treatment Clinical Trials Trials Disease 52

The Pharma Data

SEPTEMBER 27, 2021

AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe regional enteritis. 16,17 In April 2019, SKYRIZI received U.S. SKYRIZI was also approved by the ecu Commission in April 2019. ” In the analysis plans for the U.S.

Treatment 52

Treatment FDA Therapies Disease 52

The Pharma Data

NOVEMBER 2, 2020

billion in global revenues in 2019, is facing increasing competition from biosimilars. Additionally, patients who switched to bimekizumab from adalimumab at week 24 saw comparable outcomes to those taking the regimen uninterrupted. Humira, which earned $4.9 Source link.

Biosimilars 52

Biosimilars Treatment Drugs Research 52

New Drug Approvals

SEPTEMBER 29, 2024

gingivalis DNA was detected in postmortem cortices from people with AD and healthy controls, and in CSF of AD patients ( Jan 2019 news on Dominy et al., Both were reversed by treatment with COR388 ( 2020 AAIC abstract ). Findings Two Phase 1 trials of atuzaginstat were completed by June 2019. and Europe.

Small Molecule 62

Small Molecule DNA Disease Trials 62

The Pharma Data

SEPTEMBER 10, 2020

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study. 97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world data.

Treatment 52

Treatment Disease FDA Approval Clinical Trials 52

Broad Institute

NOVEMBER 6, 2024

Launched in 2017, this is a first-of-its-kind program in North America focused on improving the diagnosis, treatment, and understanding of serious immunotherapy complications, which can affect nearly every organ system.

Immune Response 125

Immune Response Medical Schools Clinical Trials Treatment 125

The Pharma Data

JUNE 28, 2021

“Despite available treatments, many people with moderate to severe forms of this disease continue to experience a relentless and burdensome cycle of skin and itch symptoms. We are encouraged that the CHMP has recognized RINVOQ’s potential as an additional treatment option for these patients.”

Treatment 52

Treatment Therapies Disease Vaccine 52

The Pharma Data

JANUARY 19, 2021

20, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). SAN DIEGO, Jan. Dr. Dennis J. The company’s subsidiary, U.S.

Treatment 52

Treatment FDA Pharmaceuticals Government 52